Date Time
Penn Researchers Use Arcuate Organoids to Study Development and Disease of Hypothalamus
A 70 day ARCO generated from control human iPSC line immunostained with nuclei marker DAPI (white), mature neuron marker NeuN (cyan) and immature neuron marker DCX (green). Image provided by Wei-Kai Huang and Sam Wong.
PHILADELPHIA- Human brain organoids are remarkable platforms for modeling features of human brain development and diseases. Building on methods to generate organoids to model different brain regions such as the cortex and the midbrain, researchers at the Perelman School of Medicine at the University of Pennsylvania have generated the first organoids of the arcuate nucleus (ARC), an essential structure in the hypothalamus that sends signals of hunger and feeling full. This part of the hypothalamus exhibits a tremendous amount of cell diversity, and is far more complex than previously modeled parts of the brain.
E-Mail
PHILADELPHIA Human brain organoids are remarkable platforms for modeling features of human brain development and diseases. Building on methods to generate organoids to model different brain regions such as the cortex and the midbrain, researchers at the Perelman School of Medicine at the University of Pennsylvania have generated the first organoids of the arcuate nucleus (ARC), an essential structure in the hypothalamus that sends signals of hunger and feeling full. This part of the hypothalamus exhibits a tremendous amount of cell diversity, and is far more complex than previously modeled parts of the brain.
In a paper published today in
Soleno Therapeutics Participates in Prader-Willi Syndrome (PWS) DCCR Town Hall
April 14, 2021 20:40 ET | Source: Soleno Therapeutics Soleno Therapeutics Redwood City, UNITED STATES
REDWOOD CITY, Calif., April 14, 2021 (GLOBE NEWSWIRE) Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, participated in a Prader-Willi Syndrome (PWS) DCCR Town Hall on Wednesday, April 14, 2021.
The event featured speakers from the PWS community who discussed the challenges of living with PWS, as well as patient and caregiver perspectives on DCCR treatment.
Dr. Bhatnagar’s remarks highlighted the unmet medical needs facing PWS patients, the Company’s ongoing commitment to obtaining regulatory approval for DCCR and an outline of the necessary steps to obtain reg
Harmony Biosciences Hosts Summit Which Sheds Light on Impact of Sleep Disruption in Rare Diseases prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Tonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome, a Rare Genetic Eating Disorder, from the French National Institute of Health and Medical Research (Inserm) Tonix Pharmaceuticals Holding Corp.
Expands Proprietary Uses of Tonix’s Potentiated Oxytocin for Intranasal Administration
Disorder Stunts Growth of Newborns and, Paradoxically, Can Cause Excessive Hunger During Childhood and Beyond
CHATHAM, N.J., Feb. 11, 2021 (GLOBE NEWSWIRE) Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced an agreement whereby Tonix has licensed technology using oxytocin-based therapeutics for the treatment of Prader-Willi syndrome and non-organic failure to thrive disease from Inserm. The licensing agreement has been negotiated and signed by Inserm Transfert, the private subsidiary of Inserm, on behalf of Inserm (the French National Institute of Health and Medical Research), Aix-Mar